📊 ELTX Key Takeaways
Is Elicio Therapeutics, Inc. (ELTX) a Good Investment?
Elicio Therapeutics is a pre-revenue pharmaceutical company burning significant cash with negative operating margins of -37.7M against zero revenue, indicating the company has not yet achieved commercial viability. Despite maintaining adequate liquidity with $18.6M in cash, the company's cash burn rate of $37M annually threatens runway, and the high debt-to-equity ratio of 6.11x combined with negative interest coverage of -1047.6x signals severe financial distress.
Elicio Therapeutics remains a pre-revenue biotech with substantial operating and free cash flow losses, so the business is not demonstrating self-sustaining profitability or commercial traction. Financial health is weak: equity is minimal, leverage is high, and current cash appears to cover only a limited runway relative to annual cash burn. While losses improved year over year, that improvement is not enough to offset the company’s funding risk and fragile balance sheet.
Why Buy Elicio Therapeutics, Inc. Stock? ELTX Key Strengths
- Adequate current liquidity position with $18.6M in cash and 2.38x current ratio
- Improving net loss trend with net income improving 23.8% YoY suggesting operational efficiency gains
- Early-stage pharmaceutical development company with potential pipeline upside if clinical programs succeed
- Net loss and diluted EPS improved year over year
- Cash of $18.56M provides near-term operating liquidity
- Current and quick ratios of 2.38x indicate adequate short-term balance sheet liquidity
ELTX Stock Risks: Elicio Therapeutics, Inc. Investment Risks
- Zero revenue generation indicates no commercial products and complete dependence on cash reserves for survival
- Severe cash burn of $37M annually with only $18.6M in cash creates critical runway risk of approximately 6 months
- Debt-to-equity ratio of 6.11x and inability to cover interest (-1047.6x coverage) indicate financial distress and high default risk
- Stockholders' equity of only $1.6M versus $24.2M in liabilities shows the company is technically insolvent from a balance sheet perspective
- Zero revenue indicates no proven commercial business yet
- Free cash flow burn of roughly $36.97M far exceeds cash reserves, implying likely financing pressure
- Debt-to-equity of 6.11x and only $1.64M of equity reflect a highly stressed capital structure
Key Metrics to Watch
- Cash burn rate and runway remaining until depletion
- Clinical trial progress and regulatory milestones for pipeline candidates
- Ability to secure additional funding through capital raises or partnerships
- Operating expenses reduction and timeline to potential revenue generation
- Quarterly cash burn relative to cash balance and funding runway
- Any transition from zero revenue to recurring product or collaboration revenue
Elicio Therapeutics, Inc. (ELTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
ELTX Profit Margin, ROE & Profitability Analysis
ELTX vs Healthcare Sector: How Elicio Therapeutics, Inc. Compares
How Elicio Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Elicio Therapeutics, Inc. Stock Overvalued? ELTX Valuation Analysis 2026
Based on fundamental analysis, Elicio Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Elicio Therapeutics, Inc. Balance Sheet: ELTX Debt, Cash & Liquidity
ELTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Elicio Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.25 indicates the company is currently unprofitable.
ELTX Revenue Growth, EPS Growth & YoY Performance
ELTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$4.5M | $-0.15 |
| Q3 2022 | N/A | -$8.8M | $-0.30 |
| Q2 2022 | $540.0K | -$8.8M | $-0.30 |
| Q1 2022 | $371.0K | -$14.2M | $-0.48 |
| Q3 2021 | N/A | -$15.6M | $-0.53 |
| Q2 2021 | N/A | -$13.2M | $-0.58 |
| Q1 2021 | N/A | -$13.1M | $-0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Elicio Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ELTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Elicio Therapeutics, Inc. (CIK: 0001601485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELTX
What is the AI rating for ELTX?
Elicio Therapeutics, Inc. (ELTX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELTX's key strengths?
Claude: Adequate current liquidity position with $18.6M in cash and 2.38x current ratio. Improving net loss trend with net income improving 23.8% YoY suggesting operational efficiency gains. ChatGPT: Net loss and diluted EPS improved year over year. Cash of $18.56M provides near-term operating liquidity.
What are the risks of investing in ELTX?
Claude: Zero revenue generation indicates no commercial products and complete dependence on cash reserves for survival. Severe cash burn of $37M annually with only $18.6M in cash creates critical runway risk of approximately 6 months. ChatGPT: Zero revenue indicates no proven commercial business yet. Free cash flow burn of roughly $36.97M far exceeds cash reserves, implying likely financing pressure.
What is ELTX's revenue and growth?
Elicio Therapeutics, Inc. reported revenue of $0.0.
Does ELTX pay dividends?
Elicio Therapeutics, Inc. does not currently pay dividends.
Where can I find ELTX SEC filings?
Official SEC filings for Elicio Therapeutics, Inc. (CIK: 0001601485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELTX's EPS?
Elicio Therapeutics, Inc. has a diluted EPS of $-2.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Elicio Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELTX stock overvalued or undervalued?
Valuation metrics for ELTX: ROE of -2,418.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELTX stock in 2026?
Our dual AI analysis gives Elicio Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELTX's free cash flow?
Elicio Therapeutics, Inc.'s operating cash flow is $-37.0M, with capital expenditures of $16.0K.
How does ELTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -2,418.8% (avg: 15%), current ratio 2.38 (avg: 2).
Is Elicio Therapeutics, Inc. carrying too much debt?
ELTX has a debt-to-equity ratio of 6.11x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.38 suggests adequate short-term liquidity.